Shanghai Yishi Pharmaceutical Technology Co., Ltd.

Primary objective: To evaluate the safety and tolerability of a single oral dose of SYH2059 tablets in healthy Chinese subjects. Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of a single oral dose of SYH2059 tablets in healthy Chinese subjects; 2) To evaluate the effect of a high-fat meal on the pharmacokinetic characteristics of a single oral dose of SYH2059 tablets; 3) To identify metabolites and study their excretion pathways after a single oral dose of SYH2059 tablets in healthy Chinese subjects; 4) To evaluate the effect of a single oral dose of SYH2059 tablets on the QTcF interval in healthy subjects; 5) To evaluate the PD characteristics of a single oral dose of SYH2059 tablets in healthy Chinese subjects.